Annual industry ranking and forecast
Generics & Biosimilars
Explore how generic drug marketing can benefit from new supply chain tools and strategies. And Sandoz US executive Sheila Frame offers insights on how the US biosimilars market is growing into its potential.
Five years on from the first US biosimilar approval, the country’s biosimilars market is starting to fulfil its potential, in part driven by a recent oncology “revolution” according to Sandoz’ Sheila Frame.
A globally co-ordinated approach to sourcing that rewards non-pricing criteria is imperative to bolster the security of the off-patent industry’s supply chain in the wake of the coronavirus pandemic, says Accord’s James Burt.
Fresenius Kabi’s decision to add radio frequency-identification (RFID) tags to 24 products used in hospital operating rooms will help the company’s hospital pharmacy customers reduce waste, increase efficiencies and facilitate tighter medication inventory control, executives told In Vivo. COVID-19-related revenue losses may push more hospitals to adopt automated RFID medication management systems to save time and reduce labor costs.
Disruptions in the supply/demand configuration of generic drugs have plagued US health care for years. Picket Pharmaceuticals, a new start-up founded by a biostatistician veteran of Africa’s war on HIV, is using the illuminating powers of big data to stabilize the generics supply chain and find untapped areas of value among thousands of products in a business that remains a mystery to physicians, payers and patients alike.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.